Malcolm I Mitchell

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects
    Malcolm Mitchell
    Lilly Research Centre, Eli Lilly and Co Ltd, Windlesham, Surrey, United Kingdom
    Clin Ther 28:881-92. 2006
  2. ncbi request reprint Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia
    Malcolm Mitchell
    Lilly Research Laboratories, Indianapolis, Indiana Electronic address
    Clin Ther 35:1890-908. 2013
  3. pmc Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial
    Prajakti A Kothare
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    BMC Clin Pharmacol 12:8. 2012
  4. pmc Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics
    S Thomas Forgue
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 63:24-35. 2007
  5. doi request reprint Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects
    Rebecca E Wrishko
    Lilly Research Laboratories, Lilly Corporate Center, DC 0730, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:610-8. 2008
  6. pmc Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
    David P McDonnell
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    BMC Psychiatry 10:45. 2010
  7. pmc Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
    Corina Loghin
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 75:538-49. 2013
  8. pmc Tadalafil pharmacokinetics in healthy subjects
    S Thomas Forgue
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 61:280-8. 2006
  9. doi request reprint Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Pacing Clin Electrophysiol 34:1116-27. 2011
  10. doi request reprint Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects
    Jill C Chappell
    From Eli Lilly and Company, Indianapolis, IN Institute of Clinical Chemistry and Laboratory Medicine Department of Medicine, University of Dresden, Dresden, Germany Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA MMS Holdings, Inc, Canton, MI Eli Lilly and Company, Windlesham, Surrey, UK Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL Detke Biopharma Consulting, LLC and Indiana University School of Medicine, Indianapolis, IN
    J Clin Psychopharmacol 34:9-16. 2014

Collaborators

Detail Information

Publications10

  1. ncbi request reprint A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects
    Malcolm Mitchell
    Lilly Research Centre, Eli Lilly and Co Ltd, Windlesham, Surrey, United Kingdom
    Clin Ther 28:881-92. 2006
    ..Prescription monitoring in the United States suggests that oral olanzapine is prescribed in doses that exceed the approved range of 5 to 20 mg/d...
  2. ncbi request reprint Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia
    Malcolm Mitchell
    Lilly Research Laboratories, Indianapolis, Indiana Electronic address
    Clin Ther 35:1890-908. 2013
    ..This was the first study, to our knowledge, in patients with schizophrenia in which olanzapine long-acting injection (LAI) was used to attempt delivery of depot formulation in multiple therapeutic doses...
  3. pmc Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial
    Prajakti A Kothare
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    BMC Clin Pharmacol 12:8. 2012
    ..This study evaluated the drug interaction potential of exenatide when administered adjunctively with oral contraceptives, given their potential concomitant use...
  4. pmc Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics
    S Thomas Forgue
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 63:24-35. 2007
    ..To evaluate the effects of gender, age, diabetes mellitus, renal and hepatic impairment on tadalafil pharmacokinetics and tolerability...
  5. doi request reprint Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects
    Rebecca E Wrishko
    Lilly Research Laboratories, Lilly Corporate Center, DC 0730, Indianapolis, IN 46285, USA
    J Clin Pharmacol 48:610-8. 2008
    ..In conclusion, after 10 days of coadministration, bosentan decreased tadalafil exposure by 41.5% with minimal and clinically irrelevant differences (<20%) in bosentan exposure...
  6. pmc Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
    David P McDonnell
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    BMC Psychiatry 10:45. 2010
    ..The authors conducted a series of parallel investigations into the possible reasons PDSS events occur...
  7. pmc Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
    Corina Loghin
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 75:538-49. 2013
    ..The effects of atomoxetine (20 and 60 mg twice daily), 400 mg moxifloxacin and placebo on QT(c) in 131 healthy CYP2D6 poor metabolizer males were compared...
  8. pmc Tadalafil pharmacokinetics in healthy subjects
    S Thomas Forgue
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Br J Clin Pharmacol 61:280-8. 2006
    ..To characterize tadalafil plasma pharmacokinetics in healthy subjects following single and multiple doses...
  9. doi request reprint Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Pacing Clin Electrophysiol 34:1116-27. 2011
    ..However, little is known about systematic changes in the QTc across contiguous days when normal volunteers are brought into a controlled inpatient environment...
  10. doi request reprint Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects
    Jill C Chappell
    From Eli Lilly and Company, Indianapolis, IN Institute of Clinical Chemistry and Laboratory Medicine Department of Medicine, University of Dresden, Dresden, Germany Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA MMS Holdings, Inc, Canton, MI Eli Lilly and Company, Windlesham, Surrey, UK Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL Detke Biopharma Consulting, LLC and Indiana University School of Medicine, Indianapolis, IN
    J Clin Psychopharmacol 34:9-16. 2014
    ....